Aptorum Group Limited (NASDAQ:APM) Sees Large Growth in Short Interest

Aptorum Group Limited (NASDAQ:APM) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 6,600 shares, a growth of 11.9% from the May 31st total of 5,900 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average trading volume of 44,300 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptorum Group stock. Murchinson Ltd. purchased a new stake in shares of Aptorum Group Limited (NASDAQ:APM) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned 0.27% of Aptorum Group as of its most recent filing with the Securities and Exchange Commission (SEC). 3.80% of the stock is owned by institutional investors.

Aptorum Group Stock Down 5.4 %

NASDAQ:APM opened at $4.38 on Monday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.20. The stock has a 50 day moving average of $4.82 and a 200-day moving average of $4.33. Aptorum Group has a 52 week low of $1.35 and a 52 week high of $17.49.

Aptorum Group Company Profile

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.